Terms: = Prostate cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346
847 results:
1. High-dose-rate Brachytherapy Monotherapy in Patients With Localised prostate cancer: Dose Modelling and Optimisation Using Computer Algorithms.
Dabic-Stankovic K; Rajkovic K; Stankovic J; Marosevic G; Kolarevic G; Pavicar B
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):378-389. PubMed ID: 38584072
[TBL] [Abstract] [Full Text] [Related]
2. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
Alrohaibani A; Osunkoya AO
Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
[TBL] [Abstract] [Full Text] [Related]
3. 21 Gy single fraction prostate hdr brachytherapy: 5-year results of a single institution prospective pilot study.
Salari K; Hazy AJ; Ye H; Sebastian E; Limbacher A; Johnson M; Mitchell B; Thompson AB; Seymour ZA; Nandalur SR; Krauss DJ
Brachytherapy; 2024; 23(3):321-328. PubMed ID: 38514368
[TBL] [Abstract] [Full Text] [Related]
4. Brachyterapy: The radiation oncologist opinion.
Tagliaferri L; Valentini V
Urologia; 2024 Feb; 91(1):8-10. PubMed ID: 38465607
[TBL] [Abstract] [Full Text] [Related]
5. Focal brachytherapy as definitive treatment for localized prostate cancer: A systematic review and meta-analysis.
Mohamad O; Nicosia L; Mathier E; Riggenbach E; Zamboglou C; Aebersold DM; Alongi F; Shelan M
Brachytherapy; 2024; 23(3):309-320. PubMed ID: 38431441
[TBL] [Abstract] [Full Text] [Related]
6. Nonsurgical salvage options for locally recurrent prostate cancer after primary definitive radiotherapy: a systematic review and meta-analysis.
Yang J; Xiong X; Liao X; Zheng W; Xu H; Wei Q; Yang L
Int J Surg; 2024 May; 110(5):3008-3020. PubMed ID: 38348896
[TBL] [Abstract] [Full Text] [Related]
7. Development of patient and catheter specific error thresholds for high dose rate prostate brachytherapy.
Koprivec D; Belanger C; Beaulieu L; Chatigny PY; Rosenfeld A; Cutajar D; Petasecca M; Howie A; Bucci J; Poder J
Med Phys; 2024 Mar; 51(3):2144-2154. PubMed ID: 38308854
[TBL] [Abstract] [Full Text] [Related]
8. Establishing a fingerprinting method for fast catheter identification in hdr brachytherapy in vivo dosimetry.
Tho D; Bélanger C; Jørgensen EB; Tanguay J; Rosales HML; Beddar S; Johansen JG; Kertzscher G; Lavallée MC; Beaulieu L
Brachytherapy; 2024; 23(2):165-172. PubMed ID: 38281894
[TBL] [Abstract] [Full Text] [Related]
9. Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis.
Watanabe K; Kamitani N; Ikeda N; Kawata Y; Tokiya R; Hayashi T; Miyaji Y; Tamada T; Katsui K
Brachytherapy; 2024; 23(2):179-187. PubMed ID: 38245406
[TBL] [Abstract] [Full Text] [Related]
10. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
11. Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized prostate cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M; Thomas SS; Cain A; Palvai S; Nageshwaran S; Zhang J; Hayden K; Cain A; Hoskin P; Ahmed I
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):90-99. PubMed ID: 38163520
[TBL] [Abstract] [Full Text] [Related]
12. Safety of high-dose rate (hdr) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series.
Thomas H; Chen JJ; Abdul-Baki H; Sabbagh A; Shaheen H; Chau OW; Malik N; Ayoub A; Hassanzadeh C; Hsu IC; Mohamad O
Brachytherapy; 2024; 23(2):173-178. PubMed ID: 38160102
[TBL] [Abstract] [Full Text] [Related]
13. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
14. Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases.
Ji J; Liu T; Yao Y; Liu W; Ning H; Wang T; Zhang G
Neoplasia; 2024 Jan; 47():100961. PubMed ID: 38142529
[TBL] [Abstract] [Full Text] [Related]
15. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB
Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Significance of Intraductal Carcinoma of the prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis.
Miyajima K; Sato S; Uchida N; Suzuki H; Iwatani K; Imai Y; Aikawa K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Honda M; Koike Y; Miki J; Miki K; Shimomura T; Yuen S; Yamada Y; Aoki M; Takahashi H; Urabe F; Kimura T
Clin Genitourin Cancer; 2024 Apr; 22(2):149-156.e1. PubMed ID: 38007354
[TBL] [Abstract] [Full Text] [Related]
17. Prospective study of hdr brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach.
Gomez-Iturriaga A; Zaragoza L; Valverde I; Perez Azorin F; Santos-Zorrozua B; Guerrero JA; Couñago F; Cacicedo J; Marban M; Santana S; Mascarell C; Novo E; Fernandez R; Garcia-Olaverri J; Urresola A; Ezquerro A; Büchser D
Radiother Oncol; 2024 Jan; 190():110024. PubMed ID: 37995851
[TBL] [Abstract] [Full Text] [Related]
18. Aberrant expression of gata3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract] [Full Text] [Related]
19. Robust stochastic optimization of needle configurations for robotic hdr prostate brachytherapy.
Gerlach S; Siebert FA; Schlaefer A
Med Phys; 2024 Jan; 51(1):464-475. PubMed ID: 37897883
[TBL] [Abstract] [Full Text] [Related]
20. A robust evaluation of 49 high-dose-rate prostate brachytherapy treatment plans including all major uncertainties.
Kennedy AC; Douglass MJJ; Santos AMC
J Appl Clin Med Phys; 2024 Feb; 25(2):e14182. PubMed ID: 37837652
[TBL] [Abstract] [Full Text] [Related]
[Next]
